4.6 Review

Targeting HER3 for cancer treatment: a new horizon for an old target

Journal

ESMO OPEN
Volume 8, Issue 1, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.esmoop.2023.100790

Keywords

HER3; breast cancer; lung cancer; ADCs; patritumab deruxtecan

Categories

Ask authors/readers for more resources

Human epidermal growth factor receptor 3 (HER3) is a member of the HER family with weak oncogenic power, but can enhance oncogenesis, metastasis, and drug resistance through heterodimerization with HER2 and/or EGFR. Therapeutic targeting of HER3 through monoclonal antibodies or bispecific antibodies has shown unsatisfactory results, while antibody-drug conjugates have demonstrated promising activity in cancer treatment.
Human epidermal growth factor receptor 3 (HER3) is a member of the human epidermal growth factor receptors family, having as its main ligands neuregulins 1 and 2. Although its poor tyrosine kinase activity entails a weak oncogenic power on its own, HER3 can heterodimerize with HER2 and/or epidermal growth factor receptor (EGFR), leading to a drastic enhancement of transphosphorylation and activation of downstream signaling pathways, ultimately promoting oncogenesis, metastatic dissemination, and drug resistance. Given its ubiquitous expression across solid tumors, multiple efforts have been done to therapeutically target HER3 by blocking either the ligand binding domain or its dimerization with other receptors. Treatment with anti-HER3 monoclonal antibodies or bispecific antibodies, both as single agents and in combination with other compounds, unfortunately led to unsatisfactory results across several tumor types. The HER3-directed delivery of cytotoxic payloads through antibody-drug conjugates has recently demonstrated encouraging activity in several tumor types, however, suggesting a potential role for the therapeutic targeting of HER3 in cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available